Recent News

• 05.01.2025 - Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
• 04.29.2025 - APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
• 04.29.2025 - NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
• 04.02.2025 - Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025

Recent Filings

• 04.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - EX-99.1 EX-99.1
• 04.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.28.2025 - EX-99.1 EX-99.1
• 04.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.16.2025 - EX-99.1 EX-99.1
• 04.16.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.15.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.01.2025 - EX-99.1 EX-99.1
• 04.01.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]